Riliprubart
- Generic Name
- Riliprubart
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2756228-76-7
- Unique Ingredient Identifier
- I31869XDP8
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 160
- Registration Number
- NCT06290141
- Locations
- 🇧🇷
PSEG Centro de Pesquisa Clinica Site Number : 0760009, Sao Paulo, São Paulo, Brazil
🇨🇿Investigational Site Number : 2030002, Pardubice, Czechia
🇨🇿Investigational Site Number : 2030001, Praha 2, Czechia
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT06290128
- Locations
- 🇺🇸
NeuroMedical Clinic of Central Louisiana- Site Number : 8400031, Alexandria, Louisiana, United States
🇺🇸Henry Ford Hospital- Site Number : 8400025, Detroit, Michigan, United States
🇺🇸Columbia University Irving Medical Center- Site Number : 8400003, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath